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Abstract 
Induced pluripotent stem (iPS) cells, somatic cells reprogrammed to 
the  pluripotent  state  by  forced  expression  of  defined  factors, 
represent a uniquely valuable resource for research and regenerative 
medicine.  However,  this  methodology  remains  inefficient  due  to 
incomplete  mechanistic  understanding  of  the  reprogramming 
process.  In  recent  years,  various  groups  have  endeavoured  to 
interrogate  the  cell  signalling  that  governs  the  reprogramming 
process, including LIF/STAT3, BMP, PI3K, FGF2, Wnt, TGF and MAPK 
pathways,  with  the  aim  of  increasing  our  understanding  and 
identifying new mechanisms of improving safety, reproducibility and 
efficiency.  This  has led to a unified model  of  reprogramming that 
consists of 3 stages: initiation, maturation and stabilisation. Initiation 
of  reprogramming  occurs  in  almost  all  cells  that  receive  the 
reprogramming  transgenes;  most  commonly  Oct4,  Sox2,  Klf4  and 
cMyc, and  involves  a  phenotypic  mesenchymal-to-epithelial 
transition.  The  initiation  stage  is  also  characterised  by  increased 
proliferation and a metabolic switch from oxidative phosphorylation 
to  glycolysis.  The  maturation  stage  is  considered  the  major 
bottleneck  within  the  process,  resulting  in  very  few  “stabilisation 
competent” cells progressing to the final stabilisation phase. To reach 
this stage in both mouse and human cells, pre-iPS cells must activate 
endogenous  expression  of  the  core  circuitry  of  pluripotency, 
comprising  Oct4,  Sox2,  and Nanog,  and  thus  reach  a  state  of 
transgene  independence.  By  the  stabilisation  stage,  iPS  cells 
generally use the same signalling networks that govern pluripotency 
in embryonic stem cells. These pathways differ between mouse and 
human  cells  although  recent  work  has  demonstrated  that  this  is 
context  dependent.  As  iPS  cell  generation  technologies  move 
forward, tools are being developed to interrogate the process in more 
detail,  thus  allowing  a  greater  understanding  of  this  intriguing 
biological phenomenon. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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INTRODUCTION   
Pluripotency, the ability of a single cell to give rise to all cells within 
an entire living organism, is of great biological interest both in terms 
of understanding developmental mechanisms as well as the medical 
potential  that  pluripotent  stem  cells  possess.  However,  our 
understanding  of  the  cell  signalling  networks  underlying  this 
complex process still remains incomplete. The first pluripotent stem 
cells  were  isolated  from  mouse  blastocysts  simultaneously  by  2 
groups in 1981[1,2]. This was replicated 17 years later using human 
blastocysts[3].  Embryonic  stem (ES) cells  have since been isolated 
from  other  species  including  rhesus  monkeys[4] and  rats[5,6].  Both 
human and mouse ES cells have provided and invaluable resource to 
understand the basic biology of the pluripotent state. 
A  “core  circuitry”  of  homeodomain  transcription  factors,  Oct4[7], 
Sox2[8] and Nanog[9], governs pluripotency in both mouse and human 
ES cells[10]. These transcription factors are expressed both in vivo in 
the inner cell mass (ICM) of the blastocyst and in vitro, in pluripotent 
cells.  These 3 factors closely  interact within  the cell;  for  example 
Oct4 and  Sox2  have  been  shown  to  form  a  heterodimeric 
transcription complex[11-13] and all 3 factors share target genes[14,15]. 
This interaction facilitates the precise regulation of the core circuitry 
necessary  to  maintain  the  pluripotent  state;  for  instance  Oct4 
overexpression  leads  to  endoderm  and  mesoderm  differentiation 
whereas blockade of  Oct4 induces trophoblast differentiation[7]. This 
may be explained by its biphasic role in  Nanog regulation whereby 
low levels of  Oct4 result in upregulation of  Nanog whereas higher 
levels of  Oct4  result in downregulation of  Nanog[15]. Similarly, small 
increases in  Sox2 expression or  ablation  of  Sox2 expression both 
induce multilineage differentiation[16].  Blockade of  Nanog  does  not 
induce differentiation, thus indicating that  Nanog’s role in the core 
circuitry  of  pluripotency is  to stabilise  the pluripotent  state rather 
than acting as a housekeeper. However, Nanog knockdown does lead 
to an increased capacity for differentiation into primitive ectoderm[9]. 
The  core  pluripotency  circuitry  is  also  autoregulatory  since  all  3 
factors have been shown to regulate the expression of each other as 
well as themselves[14,15,17]. Interestingly, SOX2 is dispensable for the 
activation of Oct4/Sox2 target genes since forced expression of Oct4 
is  able  to  rescue  pluripotency  in  Sox2-/- cells,  however,  Sox2 
expression is necessary to maintain Oct4 expression[8]. Although it is 
clear  that  OCT4,  SOX2  and  NANOG  occupy  the  top  level  of  the 
pluripotency hierarchy, these core factors also regulate a wide range 
of genes associated with pluripotency signalling networks including 
Stat3, Zic3, Tdgf1, Lefty/Ebaf, Dkk1 and Frat2[14].
With the emergence of this complex molecular inter-play of dosage 
dependency  between  hierarchical  transcription  factors  in  the 
maintenance of the somewhat unstable pluripotent ground state, it 
seems  surprising  that  simply  over-expressing  these  factors  in 
somatic  cells  can  induce  the  pluripotent  state.  However,  the 
collective seminal studies of Yamanaka and Thomson show this to be 
feasible  in  their  descriptions  of  reprogramming  somatic  cells  to 
induced Pluripotent Stem (iPS) cells[18-20].  
The original iPS cell reprogramming strategy published by Takahashi 
et  al[19] 7  years  ago remains  robust  and largely  unaltered to  the 
present  day.  The “Yamanaka factors”,  Oct4,  Sox2,  Klf4  and cMyc 
were constitutively expressed using genome integrating retroviruses 
in both mouse[18]  and subsequently human[19] fibroblasts, and under 
ES cell culture conditions were able to induce pluripotency. To date, 
this methodology is still widely used, however, various adaptations 
to the method of vector delivery and reprogramming factors (Table 
1)  have  been  made.  Advances  in  vector  delivery  have  generally 
been  made to  either  improve  efficiency  or  safety,  by  preventing 
integration of the transgenes into the genome. For example, iPS cells 
have now been successfully generated using episomal plasmids[21], 
Sendai  viruses[22]  and  piggyBac  transposons[23]  to  deliver  the 
reprogramming factors  and even proteins[24]  or  small  molecules[25] 
alone.  Many  divergent  cell-types  have  been  successfully 
reprogrammed to pluripotency including neural stem cells[26], neural 
progenitor  cells[27],  keratinocytes[28],  B  lymphocytes[29],  meningeal 
membrane  cells[30],  peripheral  blood  mononuclear  cells[31]  and 
pancreatic   cells[32].  Often  the  minimal  factors  necessary  to 
reprogram  a  cell  depend  on  the  endogenous  “stemness”  of  the 
starting cell, for example, neural stem cells can be reprogrammed 
using  Oct4 alone  since  they  express  high  levels  of  the  other 
Yamanaka factors[26]. 
The common aspiration is that iPS cells will provide an autologous 
source of cells for a multitude of regenerative medicine therapies in 
the future and clinical trials using iPS cells have begun[33]. However, 
the most immediate utility of iPS cell technologies is the ability to 
study  patient-derived  cells  in  the  lab.  iPS  cells  present  the 
opportunity to study a range of diseases in novel ways by isolating 
and  reprogramming  patient-specific  cells  and  then  differentiating 
them into the cell type of interest. For example, iPS cells have been 
generated from patients suffering from a wide range of disorders 
including  Duchenne  muscular  dystrophy,  Parkinson’s  disease, 
Huntingdon’s  disease,  type Ⅰ diabetes  and  Down’s  syndrome 
(reviewed  in[34]).  In  addition,  cells  such  as  disease-specific 
cardiomyocytes, which would be difficult to obtain from patients, can 
also be generated and used to test specific drugs[35]. In summary, the 
generation of iPS cells has stimulated the growth of a hugely active 
new  area  of  research  with  promise  to  revolutionise  medicine. 
However, the reprogramming process remains extremely inefficient 
and the basic molecular understanding of a process that does not 
appear to readily  occur in nature is  only  just  being unravelled.  A 
greater understanding of the basic biology will lead to more efficient 
methodologies  for  iPS  cell  reprogramming  in  vitro and  also 
potentially  lead  to  strategies  to  therapeutically  manipulate 
differentiated  cells  in  vivo to  become  stem  cells  and  repair  or 
regenerate diseased tissues. 
IPS REPROGRAMMING IS A STEPWISE PROCESS  
Much  progress  has  been  made  in  recent  years  to  define  the 
molecular mechanisms involved in iPS cell reprogramming. This has 
led to the general acceptance of the model proposed by Samavarchi-
Tehrani  et al[36] that reprogramming consists of 3 phases: initiation, 
maturation and stabilisation (Summarised in Figure 1). Throughout 
reprogramming various changes occur not only to the cell phenotype 
but also to gene and non-coding RNA expression, epigenetic status 
and metabolism. In this review we will focus on cell signalling during 
the  3  stages  of  iPS  cell  reprogramming  whilst  other  aspects  are 
reviewed elsewhere by Papp et al[37] and Jia et al[38].  
INITIATION 
The  initiation  phase  of  reprogramming  occurs  in  virtually  all 
successfully  transfected  cells[39] and  is  characterised  by  somatic 
genes  being  switched  off  by  methylation,  an  increase  in  cell 
proliferation, a metabolic switch from oxidative phosphorylation to 
glycolysis, reactivation of telomerase activity and a mesenchymal-
to-epithelial  transition (MET)[40].  MET is a feature of both mouse[41] 
and human[42] somatic cell reprogramming and involves the loss of 
mesenchymal characteristics such as motility and the acquisition of 
epithelial characteristics such as cell polarity and expression of the 
cell  adhesion  molecule   E-CADHERIN,  perhaps  explaining  why  E-
cadherin can replace Oct4 in the reprogramming process[43]. MET and 
the opposite transition, epithelial-to-mesenchymal transition (EMT), 
are key features of embryogenesis[44], tumour metastasis[45] and both 
mouse[46] and human[47] ES cell differentiation. Interestingly, the MET 
that marks the initiation of cellular reprogramming is reversible since 
removal of  the reprogramming factors from mouse “pre-iPS” cells 
after  induction  of  reprogramming  has  been  shown  to  lead  to 
reversion  of  the  cells  to  a  mesenchymal  phenotype[36],  thus 
demonstrating that continued transgene expression is necessary to 
allow cells to progress to the maturation stage. 
Mechanistically,  Sox2  suppresses  expression  of  Snail,  an  EMT 
inducer[48], and  Klf4 induces  E-cadherin expression, thus promoting 
MET[41]. In addition, Maekawa et al[49] have shown that the Glis family 
zinc finger 1 protein Glis1 can substitute cMyc in the reprogramming 
cocktail by inducing MET, thus initiating iPS cell reprogramming. MET 
can also be induced by chemicals, for example, various groups have 
demonstrated  the  ability  of  transforming  growth  factor  (TGF) 
inhibition  to  enhance  the  initiation  stage  of  both  mouse[50,51] and 
human[42] somatic cell reprogramming. This observation is supported 
by the finding that addition of recombinant TGF abrogates iPS cell 
formation[42] and is likely due to the EMT-inducing action of  TGF 
signalling, which then prevents the MET that is critical to successful 
iPS cell reprogramming. TGF signalling promotes EMT  via a wide 
variety  of  mechanisms,  including  mediating  the  disassembly  of 
junctional  complexes,  reorganising the cell  cytoskeleton,  and EMT 
gene  activation[52].  Various  TGF inhibitors  have  been  used  to 
promote reprogramming, including A-83-01[41,53],  E616452[25,50]  (also 
known  as  RepSox)  and  SB431542[42]  (Table  2).  In  addition  to 
promoting MET, TGFβ inhibitors promote  Nanog expression[50], thus 
providing  2  potential  mechanisms  for  their  ability  to  enhance 
reprogramming. Mitogen-activated protein kinase (MAPK) signalling, 
activated by TGFβ,  further induces the expression of  mesodermal 
genes[52].  Inhibitors  of  MAPK  signalling  such  as  PD0325901  have 
therefore been used in combination with TGF inhibitors to promote 
MET[42].
Bone morphogenetic protein (BMP) signalling also plays an important 
role  in  the  initiation  stage  of  mouse  iPS  cell  reprogramming  by 
promoting  MET  via upregulation  of  epithelial  genes  such  as  E-
cadherin, Occludin and Epithelial cell adhesion molecule[36]. Chen et 
al[54]  have shown that BMPs can replace  Klf4  in the reprogramming 
cocktail,  allowing  mouse  embryonic  fibroblasts  (MEFs)  to  be 
reprogrammed  using  Oct4  alone.  However,  constitutive  BMP 
activation  prevents  human somatic  cell  reprogramming.  This  was 
discovered through the observation that a naturally occurring  Alk2 
mutation,  which  causes  fibrodysplasia  ossificans  progressiva  in 
humans, prevents iPS cell reprogramming and that this blockade can 
be rescued by inhibition of the ALK2 receptor[55].
Increased  proliferation  has  been  observed  in  cells  undergoing 
reprogramming as early as 3 d after induction of reprogramming[56] 
and is likely to be initiated by  cMyc transgene expression[57].  Lin28 
expression and  p53 knockdown also increase the efficiency of iPS 
cell reprogramming by stimulating cell  proliferation[39].  Specifically, 
LIN28 has been shown to regulate cell cycle genes such as Cyclin A, 
Cyclin B and Cdk4[58] whilst p53 induces cell cycle arrest via p21 and 
thus p53 knockdown promotes proliferation[59]. 
Fibroblast growth factor (FGF) signalling has also been implicated at 
the initiation stage[60]. Araki et al[61] show that Fgf4 is upregulated on 
day 3 after  induction  of  reprogramming in  MEFs and Jiao  et  al[60] 
show that FGF2 can improve the reprogramming efficiency in the 
early phases of mouse somatic cell reprogramming, whereas it has 
adverse effects in the later stages. Mechanistically, this group have 
shown  that  FGF2  promotes  the  early  stages  of  reprogramming 
through  accelerating  cell  proliferation,  facilitating  MET  and 
eliminating  extracellular  collagens.  In  addition  to  an  increased 
proliferation  rate,  the  minority  of  cells  that  undergo  successful 
reprogramming also exhibit resistance to apoptosis and senescence, 
by transgene expression[56]. Recent studies have shown that miR-302 
expression  allows  cells  to  overcome  reprogramming-induced 
senescence[62] and that silencing of the INK4/ARF locus is also likely 
to be involved, since INK4/ARF blockade improves reprogramming 
efficiency[63,64].  The  INK4/ARF  locus  encodes  tumour  suppressor 
genes  that  activate  the  retinoblastoma  and  p53  pathways.  Its 
inactivation  therefore  blocks  apoptosis  and  senescence  and 
facilitates reprogramming.
The initiation phase is also characterised by a metabolic switch from 
oxidative phosphorylation to glycolysis[65] that occurs around 7 d after 
induction  of  reprogramming[66] and involves phosphatidylinositol-3-
kinase (PI3K)/AKT  signalling[53,67].  For  example,  Chen  et  al[67] have 
demonstrated  that  the  PI3K/AKT  pathway  was  activated  during 
reprogramming in parallel with the upregulation of glycolytic gene 
expression, showing specifically that AKT activated 2 key glycolytic 
regulators,  AS1060 and PFKB2.  Zhu et  al[53]  have also shown that 
PS48,  an  activator  of  the  PI3K/AKT  pathway,  is  able  to  enhance 
reprogramming by upregulating glycolytic genes. By switching their 
metabolism from oxidative phosphorylation to anaerobic glycolysis, 
pre-iPS cells assume an ES cell-like phenotype[68]. ES cells are likely 
to have developed this form of metabolism as an adaptation to the 
hypoxic  in  vivo  environment of  the early  embryo[69].  Interestingly, 
various groups have shown that iPS cell reprogramming is enhanced 
by hypoxia[70,71], likely due to the acceleration of this metabolic shift. 
MATURATION 
Tanabe et al[72]  have recently identified the maturation stage of iPS 
cell  reprogramming  as  being  a  major  bottleneck  in  the  process, 
which  is  likely  to  account  for  the  low  efficiency  of  the  process 
generally. They demonstrate that LIN28, but not NANOG, shp53 or 
CYCLIN  D1,  promotes  maturation  of  iPS  cells.  During  maturation, 
epigenetic  changes  occur  allowing  expression  of  the  first 
pluripotency-associated  genes[40].  These  genes  include  Fbxo15, 
Sall4, Oct4, Nanog and Esrrb. Interestingly, Esrrb has been shown to 
be  sufficient  to  reprogram  MEFs  in  collaboration  with  Sox2  and 
Oct4[73].
LIF/STAT3 signalling is required for the maturation phase of mouse 
iPS cell reprogramming[74]. Interestingly, pre-iPS cell colony formation 
has been observed in the absence of LIF, however, beyond day 6 of 
reprogramming  these  colonies  detach.  This  is  likely  due  to  the 
requirement that cells undergoing the reprogramming process have 
for LIF signalling to maintain cMyc expression[75]. In addition, Tang et 
al[74] demonstrate that LIF/STAT3 activation induces earlier formation 
of an increased number of pre-iPS cell colonies. Mechanistically, this 
group  demonstrate  that  LIF/STAT3  signalling  is  required  for 
demethylation  of  pluripotency-associated  gene  promoters. 
Specifically, STAT3 signalling was shown to directly block the action 
of the DNA methyltransferase DNMT1 and Histone deacetylases 2, 3 
and 8. 
Wnt  signalling  also  enhances  the  maturation  phase  of  mouse 
somatic cell reprogramming whereby exogenous stimulation of the 
pathway  using  Wnt3a  between  days  6  and  9  after  induction  of 
reprogramming  enhances  the  formation  of  Nanog positive 
colonies[76]. Various groups have suggested that expression of Nanog 
is necessary for cells to advance from the maturation phase to the 
stabilisation  stage[39,77]  and thus,  Samavarchi  et  al[36] suggest  that 
Nanog  expression alone is responsible for mediating the transition 
from  pre-iPS  cells  to  stably  reprogrammed  cells.  This  group 
demonstrate that removal of the reprogramming factors from mouse 
iPS cells at day 9 after induction of reprogramming did not induce 
phenotypic  reversion.  Other  groups,  however,  have  reported 
different time points for the stabilisation stage, including day 11[78,79] 
and day 16[80], suggesting that this can vary depending on discrete 
protocols  and  culture  variations.  It  is  clear  that  there  remains 
substantial  information  to  be  learned  regarding  this  critical 
intermediary step but NANOG appears to play a pivotal role in iPS 
cell maturation.
STABILISATION 
Only around 1% of cells that initiate reprogramming make it to the 
stabilisation stage[72]. This can be explained by the observation made 
by Golipour  et al[81] that not all cells are “stabilisation competent”. 
This group identify a gene expression signature that distinguishes 
stabilisation competent and stabilisation incompetent cells and show 
that  stabilisation  competent  cells  require  transgene  repression  to 
enter  this  stage.  Since  the stabilisation  stage is  characterised by 
transgene independence, only cells that have activated endogenous 
pluripotency gene expression are able to maintain pluripotency at 
this  late  stage.  Endogenous  pluripotency  gene  expression  is 
facilitated by demethylation  of  pluripotency gene promoters,  thus 
explaining why various DNA and histone methyltransferase inhibitors 
have been shown to  accelerate iPS  cell  reprogramming,  amongst 
other small molecules (Table 2). This may also explain the ability of 
the H3K27 demethylase UTX to substitute for some of the original 
reprogramming factors[82]. 
The  end-point  of  iPS  cell  reprogramming  is  a  matter  of  some 
controversy. For example, the stabilisation stage of mouse iPS cell 
reprogramming involves X chromosome reactivation whereas human 
iPS cell reprogramming does not[83]. X chromosome inactivation is a 
process that occurs as female embryonic cells, which have 2 active X 
chromosomes, commit to differentiation. This feature of human ES 
and human iPS cells, amongst others (reviewed in[84]), means that 
they  represent  the  primed  pluripotent  state.  Human  iPS  cells 
generated in the presence of ACTIVIN/NODAL and FGF2 ligands are 
stabilised  in  this  primed  state  whereas  mouse  iPS  cells 
reprogrammed  in  the  presence  of  LIF  and  BMP4  can  be  fully 
reprogrammed to the uncommitted naïve ground state (Figure 2). 
Interestingly, human dermal fibroblasts (HDFs) have been shown to 
give  rise  to  naïve  human  iPS  cells  when  reprogrammed  in  the 
presence  of  LIF,  FGF2  and  TGF 1  plus  inhibitors  of  c-Jun  NH2-β
terminal kinase, p38, MAPK and glycogen synthase kinase 3 (3i)[85], 
thus demonstrating that the cell signalling context is critical to the 
determination of naïve and primed pluripotency rather than the two 
states representing a species difference. The derivation of various 
novel  stem  cell  lines,  including  intermediate  epiblast  stem  cells 
which  exhibit  dual  responsiveness  to  LIF  and  ACTIVIN/NODAL 
signalling[86],  has  challenged  the  concept  of  2  distinct  pluripotent 
states, instead suggesting that a spectrum of pluripotency exists, an 
idea we develop in Hawkins et al[87]. Thorough investigation into this 
spectrum  of  pluripotency,  and  therefore  the  transition  from 
pluripotent  cells  to  differentiated  cells,  should  accelerate  the 
delineation  of  mechanisms  occurring  throughout  the  reverse 
process, from a somatic cell to an iPS cell.
CONCLUSION  
A  proposed  model  for  the  signalling  networks  required  for  the 
various stages of mouse and human iPS cell reprogramming can be 
found in Figure 1. However, this knowledge is still vastly incomplete. 
New technological advances are required to thoroughly interrogate 
the contribution of a wide range of signalling pathways to somatic 
cell  reprogramming.  One  of  the  limitations  of  many  current 
approaches is the inability to track reprogramming cell signalling in 
real-time since cells must be sacrificed to obtain data, for example 
for  microarray  analysis[36],  fluorescence-activated  cell  sorting  or 
protein extracts[78] at various time points. Some advances have been 
made to track reprogramming cells in real-time, for example, Smith 
et al[88] carried out time-lapse imaging with the aim of tracking single 
cells  undergoing  the  reprogramming  process.  However,  they 
concluded  that  this  was  virtually  impossible.  We  are  currently 
interrogating  the  role  of  cell  signalling  networks  in  iPS  cell 
reprogramming using a range of GFP reporter HDF lines activated by 
transcription  factors  involved  in  relevant  cell  signalling  pathways. 
This allows us to monitor signalling pathway activity throughout an 
entire iPS cell reprogramming experiment in real-time. We anticipate 
this  will  enable  us  to  temporally  map the  contribution  of  a  wide 
range  of  signalling  pathways  to  iPS  cell  reprogramming,  thus 
illuminating this enigmatic biological phenomenon.
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FIGURE LEGENDS
Figure  1   The  key  stages  in  (A)  mouse  and  (B)  human 
induced  pluripotent  stem  cell  reprogramming  and  the 
signalling pathways that regulate them.
Figure  2   The  core  signalling  networks  that  maintain 
pluripotency in (A) naive and (B) primed pluripotent cells.
Table 1  Factors that have been shown to achieve induced pluripotent stem cell 
reprogramming
Reprogramming fact
or
Human/mouse            Ref.
Oct4 Both Takahashi et al[18,1
9]
Sox2 Both Takahashi et al[18,1
9]
cMyc Both Takahashi et al[18,1
9]
Klf4 Both Takahashi et al[18,1
9]
Nanog Human Yu et al[20]
Esrrb Mouse Feng et al[73]
Glis1 Both Maekawa et al[49]
E-cadherin Mouse Redmer et al[43]
shp53 Both Hanna et al[39]
Lin28 Both Hanna et al[39]
UTX Both Mansour et al[82]


Table 2  Small molecules that enhance induced pluripotent stem cell reprogramming
Small molecule              Function            Ref.
BIX-01294 Histone methyltransferase inhibitor Shi et al[51]
Bayk8644 Calcium channel agonist Shi et al[51]
RG108 DNA methyltransferase inhibitor Shi et al[51]
5-Aza-2’-Deoxycytidine DNA methyltransferase inhibitor Huangfu et al[89]
Dexamethasone Steroid glucocorticoid Huangfu et al[89]
Valproic acid HDAC inhibitor Huangfu et al[89]
Trichostatin A HDAC inhibitor Huangfu et al[89]
SAHA HDAC inhibitor Huangfu et al[89]
PD0325901 + 
CHIR99021
MAPK inhibition and GSK3 inhibition Shi et al[51], Silva et al[77]
SB 431542+ PD032590
1
TGF  inhibitorβ Lin et al[42]
And MAPK inhibitor
A-83-01 TGFβ inhibitor Li et al[41], Zhu et al[53]
E616452 TGFβ inhibitor Ichida et al[90]
AMI-5 Protein arginine methyltransferase inhibitor Yuan et al[13]
Kenpaullone Unknown “novel function” Lyssiotis et al[91]
Adapted from Feng et al[73]. SAHA: Suberoylanilide hydroxamic acid; AMI: Arginine N-Methyltransferase Inhibitor.

